On May 23, 2022, Agios Pharmaceuticals, Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with Bruce Car, Ph.D., effective as of August 1, 2022 (the “Effective Date”), which is the date following the effective date of Dr. Car's resignation as the Company's chief scientific officer. Pursuant to the Consulting Agreement, Dr. Car has agreed to assist the Company with the transition of the research and discovery science and to provide such other services as may be requested by the Company from time to time (which services will not exceed 10 hours per week).